EBMT 2021 | Prednisone with or without ECP for GvHD

Daniel Couriel • 9 Mar 2021

EBMT 2021

General Prednisone

Daniel Couriel, MD, MS, University of Utah, Salt Lake City, UT, gives an overview of a Phase II trial (NCT00609609) investigating prednisone with or without extracorporeal photopheresis (ECP) for acute graft-versus-host disease (GvHD). 51 patients were randomized to the ECP arm and 30 were randomized to prednisone alone. The ECP arm reported a higher probability of success than the prednisone alone arm, however this was not statistically significant. Success was defined as being alive, in remission and achieving an acute GvHD response without additional therapy at day 56. In patients with skin-only acute GvHD the difference between the ECP arm and the prednisone-only arm was more pronounced, with a response rate of 72% versus 57% respectively. This interview took place during the 47th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) 2021.